Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ: ZYME ) with a Overweight and raises the price target from $34 to $37.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.